^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
HF158K1
i
Other names: HF158K1, HFK1, HF 158K1, HF-158K1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
HighField Bio
Drug class:
HER2 inhibitor, Topoisomerase II inhibitor
Related drugs:
15d
HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors (clinicaltrials.gov)
P1, N=84, Recruiting, HighField Biopharmaceuticals Corporation | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Jun 2027
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
HF158K1
over2years
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors (clinicaltrials.gov)
P1, N=84, Recruiting, HighField Biopharmaceuticals Corporation | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
HF158K1
almost3years
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors (clinicaltrials.gov)
P1, N=84, Not yet recruiting, HighField Biopharmaceuticals Corporation
New P1 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
HF158K1
Share via
